Arginine reprograms metabolism in liver cancer via RBM39

分享:

简介:

  • 作者: Dirk Mossmann, Christoph Müller, Sujin Park, Brendan Ryback, Marco Colombi, Nathalie Ritter, Diana Weißenberger, Eva Dazert, Mairene Coto-Llerena, Sandro Nuciforo, Lauriane Blukacz, Caner Ercan, Veronica Jimenez, Salvatore Piscuoglio, Fatima Bosch, Luigi M. Terracciano, Uwe Sauer, Markus H. Heim, Michael N. Hall
  • 杂志: Cell
  • Doi: https://www.doi.org/10.1016/j.cell.2023.09.011
  • 出版日期: 2023 Oct 6

论文中使用的产品/服务

Quotation shows PackGene:For knockdown of Asns and Rbm39 following AAV particles were purchased from Packgene (USA): AAV-DJ[ssAAV.ALB.EGFP.miR30shRNA(mScramble). WPRE.SV40pA] (AAV-shCtrl), AAV-DJ[ssAAV.ALB.EGFP.miR30shRNA(mASNS).WPRE.SV40pA] (AAV-shAsns), AAV-DJ[ssAAV.ALB.EGFP.miR30shRNA(mRBM39).WPRE.SV40pA] (AAV-shRbm39). 5x10^11 GC in PBS were injected per mouse.

Research Field:Liver Cancer

AAV Serotype:AAV.DJ

Targeted organ:LIver

Animal or cell line strain:mouse

询价

摘要

Metabolic reprogramming is a hallmark of cancer. However, mechanisms underlying metabolic reprogramming and how altered metabolism in turn enhances tumorigenicity are poorly understood. Here, we report that arginine levels are elevated in murine and patient hepatocellular carcinoma (HCC), despite reduced expression of arginine synthesis genes. Tumor cells accumulate high levels of arginine due to increased uptake and reduced arginine-to-polyamine conversion. Importantly, the high levels of arginine promote tumor formation via further metabolic reprogramming, including changes in glucose, amino acid, nucleotide, and fatty acid metabolism. Mechanistically, arginine binds RNA-binding motif protein 39 (RBM39) to control expression of metabolic genes. RBM39-mediated upregulation of asparagine synthesis leads to enhanced arginine uptake, creating a positive feedback loop to sustain high arginine levels and oncogenic metabolism. Thus, arginine is a second messenger-like molecule that reprograms metabolism to promote tumor growth.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载